Rocket Pharmaceuticals, Inc.
NASDAQ:RCKTBiotechnology
+$0.06 today
- Market cap
- $235.60M
- Beta
- 0.47
- P/E (TTM)
- -1.7
- EPS (TTM)
- -$1.87
Volume 2.49M
Average 3.15M
RCKT Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Rocket Pharmaceuticals, Inc.NASDAQ: RCKT
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income declines year over year
Q1 FY2026 net income of $47.59M (cash outflow) fell 22.4% year over year, behind the -18.9% change in trailing-twelve-month net income. Sequentially, it rose 11.9% from the prior quarter. Over 3 fiscal years it compounded at +0.2% a year.
Context
- Net income grew in size in 2 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 8 analysts of -$28.45M (-87.2%) for the fiscal year ending Dec 2026, a slowdown from the -13.8% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$47.59M+11.9% QoQ
- Last fiscal yearDec 2025
- -$223.12M-13.8% YoY
- LTMMar 2026
- -$209.38M-18.9% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -22.4% | +268.8% | +291.2 pp |
| 1 year | -13.8% | -87.2% | -73.5 pp |
| 3-year CAGR | +0.2% | -11.8% | -12.0 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (223.12M) USD
- Year-over-year change
- +13.8%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (223.12M) | +13.8% |
| FY2024 | 2024-12-31 | (258.75M) | -5.4% |
| FY2023 | 2023-12-31 | (245.6M) | -10.7% |
| FY2022 | 2022-12-31 | (221.86M) | -31.2% |
| FY2021 | 2021-12-31 | (169.07M) | — |
Net Income vs competitors
How RCKT compares with its peers on the latest reported figures
- RCKT's LTM Mar 2026 net income of $209.38M is the 2nd largest of the 10 companies compared; the peer median is $112.39M.
- Its year-over-year change of -18.9% is the 8th highest of 9, against a peer median of +20.0%.
- Over three fiscal years its annual growth of +0.2% compares with a peer median of +15.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $288.97M | +21.3% | +24.5% | 312.1% | |
| LTM Mar 2026 | $209.38M | -18.9% | +0.2% | — | |
| LTM Mar 2026 | $196.48M | +17.4% | +13.3% | — | |
| LTM Mar 2026 | $191.78M | +37.3% | +26.6% | — | |
| LTM Mar 2026 | $167.47M | +47.3% | +15.1% | — | |
| LTM Mar 2026 | $112.39M | +18.7% | +21.8% | — | |
| LTM Mar 2026 | $103.82M | +3.1% | -8.5% | 5605.9% | |
| LTM Mar 2026 | $69.71M | +24.0% | +3.3% | — | |
LBRXLB Pharmaceuticals Inc Common Stock | LTM Mar 2026 | $39.17M | — | +20.7% | — |
| LTM Mar 2026 | $26.25M | -41.9% | -7.4% | — | |
| Peer median (excluding RCKT) | $112.39M | +20.0% | +15.1% | 2959.0% | |
Competitors are the stored peer set for RCKT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (169.07M) | (221.86M) | (245.6M) | (258.75M) | (223.12M) |
| Depreciation & Amortization | 5.37M | 6.27M | 7.1M | 9.38M | 11.03M |
| Deferred Income Tax | 3.15M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 29.24M | 31.01M | 39.41M | 43.92M | 37.06M |
| Change in Working Capital | (3.39M) | 6.08M | 13.46M | 1.92M | (8.3M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (4.83M) | 9.67M | 0 | 0 | 0 |
| Other Working Capital | 1.44M | (3.6M) | 13.46M | 1.92M | (8.3M) |
| Other Non-Cash Items | 13.53M | 370K | (9.28M) | (6.19M) | (6.68M) |
| Operating Cash Flow | (121.16M) | (178.14M) | (194.92M) | (209.72M) | (190.01M) |
| Capital Expenditures | (7.72M) | (8.62M) | (16.47M) | (5.86M) | (440K) |
| Acquisitions (Net) | 95K | 42.73M | 0 | 0 | 0 |
| Purchases of Investments | (245.88M) | (376.33M) | (390.92M) | (245.89M) | (276.55M) |
| Sales of Investments | 272.44M | 272.89M | 309.33M | 383.45M | 380.76M |
| Other Investing Activities | (95K) | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 18.85M | (69.33M) | (98.07M) | 131.71M | 103.77M |
| Debt Repayment | 201K | 172K | 139K | 0 | 0 |
| Common Stock Issued | 37.68M | 155.34M | 208.39M | 185.74M | 0 |
| Common Stock Repurchased | 0 | (47K) | 0 | 0 | (67K) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (201K) | (172K) | (132K) | 0 | 215K |
| Financing Cash Flow | 37.68M | 155.29M | 208.4M | 185.74M | 148K |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (64.63M) | (92.18M) | (84.58M) | 107.72M | (86.1M) |
| Free Cash Flow | (128.88M) | (186.76M) | (211.39M) | (215.59M) | (190.45M) |
Rocket Pharmaceuticals, Inc.
NASDAQ:RCKT
Intrinsic Alpha fair value
Locked
Current Price
$2.11
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.